Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses sequencing agents for patients with multiple myeloma.

Sequential therapy is part of the natural algorithms for the disease, Niesvizky explains. In the future, he says, he can foresee achieving minimal residual disease (MRD) negativity and hopefully offer patients disease-free and drug-free states. That will only be possible, however, once patients are randomized to receive treatment or not, depending on the MRD state, in clinical trials.

Moreover, researchers need to better define MRD, he adds. Imaging will be important and will be incorporated into that question.

Videos

Dr. Niesvizky on Sequencing Therapies for Patients With Multiple Myeloma

Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses some of the exciting changes that have occurred in the field of multiple myeloma.

There has been a large evolution in the management of these patients, he explains. Physicians have tried to change the treatment algorithms to achieve the best responses possible in all patient populations, including those who are elderly. This has helped with revised criteria.

With this, physicians will be able to begin doing early intervention with agents such as lenalidomide (Revlimid) and dexamethasone, as well as more aggressive induction consolidation and maintenance regimens.

Ruben Niesvizky, MD

Articles

Dr. Niesvizky on Sequencing Therapies for Patients With Multiple Myeloma

Dr. Niesvizky on Exciting Changes in the Multiple Myeloma Landscape